

In the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A planar implant comprising a planar support with two faces, at least one face of the support being provided with an absorbable adhesive layer which is able to adhere to human or animal tissue wherein the adhesive layer is essentially formed from at least one polymer which carries free aldehyde groups and whose aldehyde groups are able to react with nucleophilic groups of the tissue.
2. (Currently amended) The implant as claimed in claim 1, characterized in that wherein the adhesive layer is essentially formed from at least one polymer which carries free aldehyde groups and whose aldehyde groups are able to react with nucleophilic groups of the tissue, and it in particular has anti-infective properties.
3. (Currently amended) The implant as claimed in claim 1, characterized in that wherein the adhesive layer either at least partially covers[[,]] preferably or completely covers[[,]] the at least one face of the support.
4. (Previously presented) The implant as claimed in claim 1, characterized in that the adhesive layer is designed to cover the planar support only around the edges and/or to protrude beyond the edges of the planar support.
5. (Currently amended) The implant as claimed in claim 1, characterized in that wherein the adhesive layer is provided on both faces of the support.
6. (Currently amended) The implant as claimed in claim 1, characterized in that wherein the support has an adhesive layer on one face and preferably optionally has an anti-adhesive layer on the other face.
7. (Currently amended) The implant as claimed in claim 6, characterized in that wherein the anti-adhesive layer has a closed and in particular smooth surface.

8. (Currently amended) The implant as claimed in claim 1, characterized in that wherein the adhesive layer is designed as an open layer and is in particular absorbent.
9. (Currently amended) The implant as claimed in claim 1, characterized in that wherein the adhesive layer is hydrophilic and in particular is able to take up aqueous fluids by swelling.
10. (Currently amended) The implant as claimed in claim 1, characterized in that wherein the adhesive layer is present in the form of a nonwoven, in particular a three-dimensional nonwoven.
11. (Currently amended) The implant as claimed in claim 1, characterized in that wherein the adhesive layer is present in the form of an open-cell foam.
12. (Currently amended) The implant as claimed in claim 2, characterized in that wherein the polymer carrying aldehyde groups is soluble in water.
13. (Currently amended) The implant as claimed in claim 2, characterized in that wherein the polymer carrying aldehyde groups is an oxidized, in particular bioabsorbable polysaccharide.
14. (Currently amended) The implant as claimed in claim 13, characterized in that wherein the oxidized polysaccharide is one from the group comprising starch, cellulose, agar, dextran aldehyde, hyaluronic acid, alginic acid, chondroitin sulfate, and preferably or dextran polyaldehyde.
15. (Currently amended) The implant as claimed in claim 14, characterized in that wherein the proportion of glucose units oxidized to the aldehyde in the dextran polyaldehyde is at least 20%[,], preferably 35 to 100%, in particular 50 to 85%.
16. (Currently amended) The implant as claimed in claim 2, characterized in that wherein the polymer carrying aldehyde groups is an in particular branched polyethylene glycol with at least three terminal aldehyde groups.
17. (Currently amended) The implant as claimed in claim 2, characterized in that wherein the polymer carrying aldehyde groups is an in particular branched polyvinyl alcohol with at least three terminal aldehyde groups.

18. (Currently amended) The implant as claimed in claim 2, characterized in that wherein the at least one polymer carrying aldehyde groups is partially cross-linked.
19. (Currently amended) The implant as claimed in claim 1, characterized in that wherein the adhesive layer has a structured surface on its outer face.
20. (Currently amended) The implant as claimed in claim 1, characterized in that wherein the planar support is porous and flexible, and in particular is formed from a textile material.
21. (Currently amended) The implant as claimed in claim 1, characterized in that wherein the support, in particular the textile support, is at least partially absorbable, in particular completely absorbable.
22. (Currently amended) The implant as claimed in claim 1, characterized in that wherein one face of the support is provided with at least one anti-adhesive layer which is preferably optionally absorbable.
23. (Currently amended) The implant as claimed in claim 21, characterized in that wherein the anti-adhesive layer contains polyvinyl alcohol and/or carboxymethylcellulose, and in particular consists of polyvinyl alcohol.
24. (Currently amended) The implant as claimed in claim 1, characterized in that it which is designed as a hernia mesh having the adhesive layer on the face which is intended to bear on the abdominal wall, and in that the other face of the hernia mesh preferably optionally has at least one layer which is designed as an anti-adhesive layer and prevents adhesion of body tissue to the mesh.
25. (Currently amended) The implant as claimed in claim 1, characterized in that it which is designed as a patch which has the adhesive layer on at least one face.
26. (Currently amended) The implant as claimed in claim 1, characterized in that it which is present as a tube section which is designed for connection of tubular hollow organs.
27. (Currently amended) Provision of the The implant as claimed in claim 1, for an internal application in an organism, in particular in the area of wounds.

28. (Currently amended) Provision of the The implant as claimed in claim 27, wherein the planar support being connected on both faces to an adhesive layer for apposition of vertical and horizontal tissue layers, the planar implant preferably optionally being absorbable.
29. (New) The implant as claimed in claim 14, wherein the proportion of glucose units oxidized to the aldehyde in the dextran polyaldehyde is 35 to 100%.
30. (New) The implant as claimed in claim 14, wherein the proportion of glucose units oxidized to the aldehyde in the dextran polyaldehyde is 50 to 85%.